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Abstract 
Genetic factors account for up to 80% of the liability for schizophrenia and bipolar 
disorder. Genome-wide association studies (GWAS) have successfully identified several 
single nucleotide polymorphisms (SNPs) and genes associated with increased risk for 
both disorders. Single SNP analyses alone do not address the overall genomic or 
polygenic architecture of psychiatric disorders as the amount of phenotypic variation 
explained by each GWAS-supported SNP is small whereas the number of SNPs/regions 
underlying risk for illness is thought to be very large. The polygenic risk score models 
the aggregate effect of alleles associated with disease status present in each individual 
and allows us to utilize the power of large GWAS to be applied robustly in small 
samples. Here we make the case that risk prediction, intervention and personalized 
medicine can only benefit with the inclusion of polygenic risk scores in imaging 
genetics research.  
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Psychiatric disorders are highly heritable, especially schizophrenia and bipolar 
disorder. Heritability is the proportion of trait variation that is accounted for by genetic 
factors, as opposed to trait variation due to environmental factors. Twin and family 
studies for schizophrenia have placed heritability around 0.8 (Sullivan et al., 2003; 
Lichtenstein et al., 2009) and between 0.6 to 0.85 for bipolar disorder (McGuffin et al., 
2003; Craddock and Sklar, 2009). After the human genome was first sequenced the 
genetics field has produced huge technological strides towards estimating heredity 
(Lander et al., 2001). The most common genetic marker is the single nucleotide 
polymorphism (SNP), a single subunit change in the DNA sequence. SNPs are located 
on a DNA chip, which is used to create a genetic profile for each individual. In turn DNA 
chips are used in genome-wide associations studies (GWAS) that estimate the 
heritability of a disorder throughout the genome by comparing healthy controls with 
patients, in a hypothesis-free way. The first disease upon which the GWAS technique 
was used was age-related macular degeneration in 2005 (Klein et al., 2005), and since 
then many genes have been implicated in macular degeneration (Fritsche et al., 2013). 
After the first GWAS studies in schizophrenia it soon became apparent there 
were no common variants that had a large influence on risk, but rather that there were 
thousands of variants of very small effect that together acted to increase or reduce 
risk. The first signs of success ins schizophrenia started to emerge in 2008 with a GWAS 
 
 
study that implicated the ZNF804A gene that almost reached the significance level 1.61 
x 10-7 (O’Donovan et al., 2008). In 2009, the SGENE consortium (Stefansson et al., 
2009) and the International Schizophrenia Consortium (Shi et al., 2009) published 
papers on other variants associated with the schizophrenia. These groups then 
combined their efforts and began publishing under the Psychiatric Genomics 
Consortium banner with papers in 2011 detailing five variants and 2013 with 13 
variants (Ripke et al., 2011; 2013). However, real progress began when the sample size 
exceeded 15,000 cases or so, with an inflection point being reached where, instead of 
discovering one variant every couple of thousand cases, variants began to be 
discovered when, on average, another 250 cases and 250 controls were added to the 
sample size. Thus, once the size of the sample had increased to >15,000 cases, the 
power to detect variants reached a point where GWAS ccould detect the effects of the 
modest size at which lots of schizophrenia-associated variants are operating. 
Then in 2014, Ripke and colleagues (Ripke et al., 2014) published 108 regions 
associated with the risk of schizophrenia. In this analysis that included over 36,989 
patients and 113,075 healthy controls, few if any candidate genes replicated; for 
example COMT, a gene implicated in the risk of schizophrenia and extensively used in 
imaging genetics had a p-value of 0.56 (Ripke et al., 2014). The same was true for the 
BDNF gene, with a p-value of 0.006. Interestingly the BDNF gene is significantly 
 
 
associated with smoking and obesity (Hallden et al., 2013), attributes with increased 
prevalence in schizophrenia (Hennekens et al., 2005). Other genes that had not been 
identified from previous schizophrenia studies were identified in the PGC2 paper and 
showed significant association with schizophrenia, such as the DRD2, a target for 
antipsychotic drugs, and the GRM3 involved in glutamatergic transmission (Ripke et al., 
2014).  
 Although genetic research in bipolar disorder is less published upon than in 
schizophrenia, susceptibility genes for bipolar disorder have also been identified 
through GWAS (Alsabban et al., 2011). The most robustly associated SNPs are located 
in the CACNA1C (Ferreira et al., 2008; Sklar et al., 2008; 2011), the ITIH3 (Sklar et al., 
2011), the TRANK1 (Chen et al., 2013), the NCAN (Cichon et al., 2011), the ANK3 
(Ferreira et al., 2008; Sklar et al., 2008; Schulze et al., 2009; Scott et al., 2009; Smith et 
al., 2009; Athanasiu et al., 2010; Tesli et al., 2011), the SYNE1 (Sklar et al., 2011; Green 
et al., 2013) and the ODZ4 gene (Sklar et al., 2011).  
The question that arises is how to utilize the predictive power of GWAS 
findings. The predictive power of genetic risk prediction is not yet useful for clinical 
applications but where genetic prediction may have utility is acting as biomarkers for 
schizophrenia and bipolar disorder traits within individuals in, e.g. imaging studies. A 
key hypothesised benefit of brain imaging approaches is their ability to decipher if and 
 
 
how genetic risk factors impact brain structure and function, especially in brain regions 
associated with disease expression.  
In the last decade a substantial amount of literature has focused on the effect 
of candidate genes on brain structure and function. Most of these studies have used 
single gene variants and risk haplotypes that were found traditionally from linkage 
studies and more recently from GWAS studies.  
Rasetti and Weinberger (2011) reviewed the literature of candidate genes in 
schizophrenia in functional magnetic resonance imaging (fMRI) studies, indexed by 
cognitive task. In the working memory (WM) domain: (i) the GAD1, GRM3, COMT, 
RGS4, CACNA1C, KCNH2, DTNBP1 and MTHFR genes have shown to impact function of 
the dorso-lateral prefrontal cortex (DLPFC), (ii) the COMT, PRODH and RGS4 have been 
associated with altered engagement of the ventrolateral prefrontal cortex (VLPFC), (iii) 
the PRODH with parietal lobe function, (iv) the NRG1, G72 and DISC1 with hippocampal 
function and last (v) the DRD2 and COMT with supragenual ACC function. In the 
cognitive control domain: (i) the DTNBP1, DRD2 and MAOA have been associated with 
DLPFC function, (ii) the DRD2 with VLPFC function, (iii) the DRD2 and MAOA with 
parietal lobe function and iv) the COMT, DRD2 and MAOA with ACC function. From all 
these genes the only ones replicated or discovered in GWAS studies are GRM3, 
CACNA1C and DRD2 (Ripke et al., 2014). The CACNA1C (Paulus et al., 2014) and 
 
 
ZNF804A (Rasetti et al., 2011) GWAS schizophrenia risk SNPs were found to be 
correlated with reduced prefrontal-hippocampal coupling during WM tasks in healthy 
controls and schizophrenia patients. Tan et al. (2012) using dynamic causal modelling 
(Friston et al., 2003) on fMRI WM data in healthy participants differentiated the effects 
of the COMT, DRD2 and AKT1 genes on the prefrontal-parietal WM maintenance and 
prefrontal-striatal WM manipulation network. Specifically, the prefrontal-parietal 
circuit is influenced only by the COMT gene, while the prefrontal-striatal circuit 
populated by the dopamine D2 receptors is affected by all three genes.  
Most imaging genetics studies in bipolar disorder have focused on the effect of 
the CACNA1C risk gene, a bipolar disorder GWAS gene, on structural and functional 
neuroimaging data, in order to better understand the contribution of genetics to 
bipolar disorder. Two structural studies have found increased grey matter volume 
(Kempton et al., 2009) and increased total cortical volume (Wang et al., 2011) 
associated with the risk CACNA1C variant. Perrier et al. (2011) using a regions of 
interest approach found increased grey matter density in the right amygdala and 
hypothalamus in participants with the risk CACNA1C SNP, while another study found 
that the CACNA1C gene influences the brainstem rather than grey matter volume 
(Franke et al., 2010).  
 
 
Studies on the effect of the CACNA1C gene on brain function that included 
bipolar disorder patients, have found increased right amygdala activity during a 
negative emotional faces task in CACNA1C risk carriers (Jogia et al., 2011; Tesli et al., 
2013). In another study during an episodic memory task carrying the CACNA1C risk 
variant resulted in a stronger decrease of hippocampal and ACC activation in bipolar 
disorder relatives, indicating an additive effect of CACNA1C variation on familial risk 
(Erk et al., 2013). Using DCM connectivity analysis, two studies found that during 
emotional processing, the presence of the CACNA1C risk allele was associated with 
decreased outflow of information from the medial frontal gyrus (Radua et al., 2013) 
and decreased visual-prefrontal effective connectivity (Dima et al., 2013). In both 
studies the findings were significantly more marked in patients than in their unaffected 
relatives and healthy controls. Although all these GWAS candidate genes imaging 
genetics studies illustrate the potential usefulness of genetic imaging, single SNP 
analyses alone do not address the overall genomic or polygenic architecture of 
schizophrenia and bipolar disorder. 
 
Polygenic scores  
A typical GWAS tests millions of SNPs for association with the disease of choice, 
but this necessitates the application of a very conservative significance threshold, 
 
 
usually 5 x 10-8 for multiple testing correction. Typically, only a small number of 
SNPs/regions survive this threshold. Nevertheless, the amount of phenotypic variation 
explained by each GWAS-supported SNP is very small whereas the number of SNPs 
underlying the risk for illness is thought to be very large (Purcell et al., 2009). For that 
reason, candidate genes studies have to be treated with cautiousness since the 
possibility of a single SNP explaining a large variance of the disease expression is slim, 
whether this is in e.g. behavioural, cognitive or neuroimaging traits.  
By utilizing the vast amount data created by GWAS studies (current sample size 
in schizophrenia > 150,000) we can calculate polygenic risk scores (PRS) for each 
individual associated with a specific disorder, e.g. schizophrenia or bipolar disorder. A 
PRS incorporates information from GWAS-SNPs and SNPs that are not genome-wide 
significant. These non significant genome-wide GWAS SNPs are meeting nominal 
significance criteria, even though it is accepted that some of them are false positives. 
The PRS thus models the aggregate effect of SNPs (alleles) associated with disease 
status present in each individual and allows us to utilize the power of large GWAS to be 
applied robustly in small samples (Ferreira et al., 2008; Purcell et al., 2009; Sklar et al., 
2011; Dudbridge et al., 2013). For example the variance explained by the current 
schizophrenia PRS is 18%, while the variance explained by the CACNA1C gene is around 
0.005% (Ripke et al., 2014). In Figure 1 we show that even with a sample size of 
 
 
>150,000 we only have 60% power to detect the impact of the CACNA1C gene. With 
the statistical power of the PRS being exponentially better than that of a single SNP it 
points to a paradigm shift in the field of imaging genetics.  
The first application of the PRS method was in schizophrenia, a study that 
supported the polygenic component of schizophrenia and its similarities with bipolar 
disorder (Purcell et al., 2009). These results were replicated in a second larger sample 
that doubled the proportion of variance explained by common variants to 6% in 
schizophrenia (Ripke et al., 2011). The polygenic model has also been successfully used 
in other traits like the body mass index (BMI; Speliotes et al., 2010), where the BMI 
PRS has shown positive association with disease expression (Peterson et al., 2011). 
Furthermore, the PRS method has been used successfully for the association of 
personality traits and mood disorders (Middeldorp et al., 2011; Luciano et al., 2012), 
depression and anxiety (Demirkan et al., 2011) and the five major psychiatric disorders 
(GROUP et al., 2013). It has also been used to differentiate genetically, for example, 
schizophrenia and autism (Vorstman et al., 2013) or schizophrenia and intelligence 
(van Scheltinga et al., 2013). The schizophrenia PRS has been correlated with 
quantitative measures of psychosis in terms of symptoms scales (Derks et al., 2012) 
and neuroimaging measures (Walton et al., 2013). Specifically the PRS for 
 
 
schizophrenia was associated positively with reduced left DLPFC during a WM 
processing paradigm (Walton et al., 2013). 
Recently, the bipolar disorder PRS has been used to examine its relationship 
with brain function and structure in individuals at familial risk for a mood disorder 
(Whalley et al., 2012; 2013). Whalley et al. (2012) showed a positive correlation 
between bipolar disorder PRS and activation of the ACC, amygdala and other limbic 
regions of the brain, areas that have been impaired in bipolar disorder expression. In 
the same cohort, the bipolar disorder PRS was significantly associated with decreased 
white matter integrity in the right superior longitudinal fasciculus (Whalley et al., 
2013). Lastly, a study found an association between the PRS for major depressive 
disorder and reduced cortical thickness in the left amygdala-medial prefrontal circuitry 
in healthy young adults (Holmes et al., 2012).  
 
Clinical relevance 
Where does the PRS fit in clinical practice? In a large Swedish population-based 
study research showed that adding a PRS on a prediction model for prostate biopsies, 
would cut the biopsies from 12% to 5%, without missing less than 1% of the aggressive 
cancers in the population (Aly et al., 2011). Marking SNPs in patients have advantages 
that other biological tests currently lack: they are cheap, easy to analyse and most 
 
 
importantly stay stable throughout the lifespan of someone life. As sample sizes 
increase exponentially in the field of psychiatry one can assume that more genetic risk 
variants will be identified in the near future, thus adding to the usefulness of genetic 
profiles substantially. The hope is that through polygenic scoring, especially in common 
diseases that seem to be affected by a large number of genes with small effects sizes, 
as is the case with schizophrenia and bipolar disorder, the road will lead to 
personalized medicine. Personalized genetics information is hopefully going to lead 
from interventional medicine to preventive medicine, which will help cut down health 
care costs. Another area of medicine where genetic information can influence greatly 
is pharmacogenomics, by keeping in mind that around 100,000 people die each year in 
the USA due to adverse drug reactions (Lazarou et al., 1998) and despite efforts to 
improve patient safety in the past few years it has not been successful (Landrigan et 
al., 2010; Phillips and Barker, 2010). Although until now there have been no robust 
findings of common genetic variants associated to drug response that could be 
translated in clinical practice in psychiatry the road has been paved for the 
identification of genetic determinants to personalized psychiatric treatment 
(Kirchheiner et al., 2005; Kim et al., 2006; Kato et al., 2010; Mrazek et al., 2011; Tansey 
et al., 2012). The efficacy of polygenic models for risk prediction, intervention and 
 
 
personalized medicine can only benefit with the inclusion of other traditional risk 
factors such as family history and age of onset (Chatterjee et al., 2013).  
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Figure 1. Power calculations for sample size for the CACNA1C gene and the 
schizophrenia PRS according to variance explained.  
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